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Wednesday, February 29, 2012 621atechniques including MALS (Multi-Angle Light Schattering), X-ray crystal-
lographyic, and SAXS (Small Angle X-ray Scattering) to better understand
the nature of the active conformation of GAC and ultimately, how the recently
described glutaminase inhibitor 968 (J.B., Wang; Cancer Cell, 2010) interacts
with GAC and renders it inactive. Our results support a model whereby GAC
binds phosphate that results in a change in glutaminase oligomerization,
which results in active tetramers as well as higher oligomeric species. Effects
of the drug 968 on the activation/oligomerization state of glutaminase will
also be discussed.
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Structure-based design efforts on antibodies are frequently hamstrung by the
general difficulty of crystallizing antibody molecules. Computational ap-
proaches are getting more success and playing a very important role in protein
structure prediction and design. A combined platform with both computational
predication and experimental verification would have a transformative research
capability on antibody engineering. We have been developing and integrating
RosettaAntibody (homology modeling and H3 loop modeling), RosettaDock
(SnugDock and EnsembleDock) and RosettaDesign (non-canonical amino
acids design) into a systematic computational pipeline. Using the targets of
M18/Anthrax complex, which has solved crystal structure, and anti-MS2/
MS2 complex, whose antibody structure is not available, the new pipeline is
capable of building homology models for antibody from its sequence, and pre-
dicting the docked antibody-antigen structures. The correct antigen epitope can
be identified by iteratively refining the predicted candidates with experimental
verifications such as interface alanine scanning. This is followed by computa-
tional CDR designs utilizing non-canonical amino acids, which can form cova-
lent bonds with epitope residues. Along with experimental confirmations, the
incorporation of the systematical computational method was proved to signif-
icantly facilitate the epitope identification and non-canonical amino acid de-
signs. These efforts eventually substantially increased the antibody-antigen
binding affinity of the two targets.
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The envelope spike on HIV surface is a non-covalent trimer of gp120 and
gp41 dimers; with gp120 responsible for binding to the CD4 receptor and
the mandatory coreceptor, CCR5 or CXCR4. Blocking the gp120-CD4 or
gp120-coreceptor interaction can block viral entry and infection. The HNG
family of peptides (sequence RINNIXWSEAMM, X= derivatized azidopro-
line) is a promising class of dual-site entry inhibitors thought to allosterically
inhibit the binding process and trap the flexible gp120 molecule in an inac-
tive state. To date, there have been no reports on the structure of the peptide
or the peptide/gp120 complex. Here we have used Molecular Dynamics to
develop a docking model in which the peptide binds in a tripartite fashion,
preventing the formation of the bridging sheet in gp120, which is necessary
for coreceptor attachment and initiation of entry. The protein undergoes sig-
nificant induced fit conformational changes involving movement of large
loops which allows the peptide to bind tightly. Our model is consistent
with experimental observations on the peptide footprint on gp120, pointing
to a hydrophobic core underneath the bridging sheet and close to the F43
pocket as the putative binding site. Our results provide an explanation for
why the stereochemistry of the triazole moiety on the proline is important
for peptide function, in addition to explaining the inactivity of D-tryptophan
in the sequence. Furthermore, saturation transfer difference (STD) NMR ex-
periments point to the I-X-P hydrophobic center on the peptide as the central
contact point in the complex, which is consistent with the peptide pose pro-
posed in MD studies. Our model may provide a unique basis for rational de-
sign of allosteric entry inhibitors of HIV and ultimately small molecule
inhibitors of viral entry.3153-Pos Board B14
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HIV-1 protease is an important drug target for the therapy of AIDS. Up to date
nine protease drugs have been approved by the U.S. Food and Drug Adminis-
tration. However, the efficacy of these drugs is limited by the drug-resistant
mutants of the protease which can become dominant in the viral population
in several months. As it often takes years of effort and millions of dollars to de-
velop a drug, evaluating the potency of a compound to combat resistance at the
early stage of drug development would is no doubt invaluable. In this study, we
present a new procedure to predict HIV protease mutants that can be resistant to
a specific compounds based on docking structure. We exploited molecular in-
teraction energy components (MIECs) between the ligand and the protease res-
idues to characterize the docking poses. A classification method called Support
Vector Machine (SVM) is then employed to distinguish resistant from non-
resistant mutants. Most interestingly, leave-one-drug-out test showed that our
strategy can be generalized to evaluate potency of new drug lead, which sug-
gests the possibility of evaluating the potency to combat resistance for small
molecules found from virtual screening.
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The objective of this study is to transport resveratrol, an antioxidant and anti-
inflammatory bioflavonoid, in the plasma to targeted sites. Resveratrol is a phy-
toalexin polyphenol that is found in natural products such as grape skins, cocoa,
and is a constituent of red wine. It appears to be a potent factor as an anti-cancer
and atheroprotective agent. The ‘‘French Paradox’’ (French suffering a rela-
tively lower incidence of coronary heart disease compared to other western so-
cieties) has been attributed to the benefits of resveratrol (as a result of higher
consumption of red wine by the French). However, it is difficult to achieve ef-
fective concentrations of resveratrol in plasma via the oral tract from natural
resveratrol-rich products. Its low aqueous solubility appears to limit the use
of resveratrol as a nutraceutical agent. We propose to employ apolipoprotein
E3 (apoE3)-containing reconstituted high density lipoproteins (rHDL) for
transportation and targeted delivery of resveratrol. rHDL are water soluble li-
poprotein complexes composed of a bilayer of phospholipids surrounded by
apoE3, which bears high affinity binding sites for the cell surface localized
low density lipoprotein receptor (LDLr). The phospholipid microenvironment
of rHDL is expected to provide a centrally located lipid milieu into which re-
sveratrol may be sequestered, and shielded from modification and/or degrada-
tion. Our data indicates that resveratrol has effectively partitioned into the
hydrophobic milieu of the phospholipid bilayer of rHDL without significant al-
teration to the conformation of apoE3. Importantly, the presence of resveratrol
did not alter the LDLr binding ability of apoE3. These results indicate that
rHDL bearing the apoE3 LDLr binding domain can serve as an effective
‘‘nanovehicle’’ to transport and potentially deliver resveratrol to targeted sites
across the cell membrane.
Funded by CSUPERB and TRDRP 17RT-0165.
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Insulin replacement therapy is central to the treatment of Type 1 diabetes mel-
litus (T1DM). Clinical trials have shown that tight glycemic control in T1DM
leads to reduction in long-term diabetic complications. In an effort to better
mimic the normal post-prandial pattern of pancreatic insulin release, meal-
time insulin analogs were developed in the 1990s using standard mutagenesis.
These analogs exhibit more rapid absorption from the subcutaneous depot due
to destabilization of the zinc insulin hexamer. Unfortunately, such conventional
analogs do not achieve the rapid ‘‘on-off’’ pharmacodynamic profiles sought in
an ideal rapid-acting insulin formulation. To circumvent this limitation, we
have investigated the utility of nonstandard protein design based on unnatural
mutagenesis. Our studies have focused on residue PheB24 at the dimer inter-
face of the insulin hexamer. Investigation of the role of this aromatic side
chain by hybrid quantum-mechanical/classical molecular mechanics (QM/
cMM) suggested that substitution of the B24 aromatic ring of its saturated
